|
CANCERS BRONCHIQUES A PETITES CELLULES
ESSAIS COMPARANT LA PLACE PRECOCE OU TARDIVE DE L’IRRADIATION THORACIQUE DANS LES MALADIES LIMITEES
|
|
Référence
|
chimiothérapie
|
radiothérapie
|
bras
|
n pts
|
SM
|
p
|
Perry,
1987(1)
|
CPA-VCR- ADR/VP16
|
50
Gy/25x/5 s
|
-
initiale (J1)
|
125
|
13,1 m
|
NS
|
-
tardive (# 4)
|
145
|
14,6 m
|
Murray,
1993 (2)
|
CPA-VCR-ADR ~
CDDP-VP16
|
40
Gy/15x/2 s
|
- initiale (s 3)
|
155
|
21,2 m
|
0,008
|
-
tardive(>#6)
|
153
|
16 m
|
Jeremic,
1997 (3)
|
CDDP-VP16
|
54 Gy (2x /j)/
36x/18j/3,6 s
|
-
initiale (J1)
|
52
|
34 m
|
0,05
|
-
tardive (s 6)
|
51
|
26 m
|
Work,
1997 (4)
|
CDDP-VP16 ~ ADR-CPA-
VCR
|
40-45 Gy split
2 x 11x/ 2 s
|
- initiale (J1)
|
99
|
10,5 m
|
NS
|
-
tardive(> #6)
|
100
|
12 m
|
Skarlos,
2001 (5)
|
Carboplatine – VP16
|
HFRT 48 Gy
1,8 Gy bid 15 x
|
-initiale
(cycle 1)
|
42
|
17 m
|
NS
|
-tardive
(cycle 4)
|
39
|
17 m
|
Takada,
2002 (6)
|
CDDP-VP16 (4 cycles)
|
HFRT 45 Gy
1,5 Gy 2x/j en 3 sem
|
- initiale (J2)
|
114
|
27,2
m
|
0;097
|
- tardive (après CT)
|
114
|
19,7
m
|
Spiro,
2006 (7)
|
CPA-VCR-ADR
~ CDDP-VP16 (3 x 2 alt)
|
40
Gy/15x/3 s
|
-initial (2è cycle)
|
159
|
13,7
m
|
0,23
|
- tardif (6è cycle)
|
166
|
15,1
m
|
Hu,
2012
(8)
|
CDDP-VP6 x 6
|
55 Gy/30x / 19J après 2
cycles
|
- volume initial
|
43
|
25,4 m
|
0,54
|
- volume réduit
|
42
|
22,1 m
|
Sun,
2013 (9)
|
CDDP-VP6 x 6 x 4
|
52,5 Gy / 5 sem
|
- 1er cycle
|
113
|
26,8 m
|
NS
|
- 3è cycle
|
109
|
24,1 m
|
Références
(1) Perry MC, Eaton WL, Propert KJ, Ware JH, Zimmer B, Chahinian AP et al. Chemotherapy with or without radiation therapy in limited small-cell carcinoma of the lung. N Engl J Med 1987; 316(15):912-918.
(2) Murray N, Coy P, Pater JL, Hodson I, Arnold A, Zee BC et al. Importance of timing for thoracic irradiation in the combined modality treatment of limited-stage small-cell lung cancer. The National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1993; 11(2):336-344.
(3) Jeremic B, Shibamoto Y, Acimovic L, Milisavljevic S. Initial versus delayed accelerated hyperfractionated radiation therapy and concurrent chemotherapy in limited small-cell lung cancer: a randomized study. J Clin Oncol 1997; 15(3):893-900.
(4) Work E, Nielsen OS, Bentzen SM, Fode K, Palshof T. Randomized study of initial versus late chest irradiation combined with chemotherapy in limited-stage small-cell lung cancer. Aarhus Lung Cancer Group. J Clin Oncol 1997; 15(9):3030-3037.
(5) Skarlos DV, Samantas E, Briassoulis E, Panoussaki E, Pavlidis N, Kalofonos HP et al. Randomized comparison of early versus late hyperfractionated thoracic irradiation concurrently with chemotherapy in limited disease small-cell lung cancer: a randomized phase II study of the Hellenic Cooperative Oncology Group (HeCOG). Ann Oncol 2001; 12(9):1231-1238.
(6) Takada M, Fukuoka M, Kawahara M, Sugiura T, Yokoyama A, Yokota S et al. Phase III Study of Concurrent Versus Sequential Thoracic Radiotherapy in Combination With Cisplatin and Etoposide for Limited-Stage Small-Cell Lung Cancer: Results of the Japan Clinical Oncology Group Study 9104. J Clin Oncol 2002; 20(14):3054-3060.
(7) Spiro SG, James LE, Rudd RM, Trask CW, Tobias JS, Snee M et al. Early compared with late radiotherapy in combined modality treatment for limited disease small-cell lung cancer: a London Lung Cancer Group multicenter randomized clinical trial and meta-analysis J Clin Oncol 2006; 24(24):3823-3830
(8) Hu X, Bao Y, Zhang L, Guo Y, Chen YY, Li KX, et al. Omitting elective nodal irradiation and irradiating postinduction versus preinduction chemotherapy tumor extent for limited-stage small cell lung cancer: interim analysis of a prospective randomized noninferiority trial. Cancer 2012 Jan 1;118(1):278-87.
(9) Sun JM, Ahn YC, Choi EK, Ahn MJ, Ahn JS, Lee SH, et al. Phase III trial of concurrent thoracic radiotherapy with either first- or third-cycle chemotherapy for limited-disease small-cell lung cancer. Ann Oncol 2013 Aug;24(8):2088-92
|